Actemra/RoActemra approved by the European Commission to tre

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has extended the marketing authorisation for Actemra®/RoActemra® (tocilizumab) to include the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.1 This ...

Related Keywords

Ghana , Australia , Japan , United States , Canada , United Kingdom , Switzerland , Australian , American , Levi Garraway , Actemra Roactemra , Chugai Pharmaceutical Co Ltd , Genentech , Gilead Sciences Inc , European Union , Committee For Medicinal Products Human Use , University Of Oxford , University Of Oxford Randomised Evaluation , European Commission , Drug Administration , World Health Organization , Head Of Global Product Development , Journal Of The American Medical Association , Australian Therapeutic Goods Administration , Approval Of Roche Products Pty Ltd , Roche Group , European Medicines Agency , Medicinal Products , Human Use , Chief Medical Officer , Global Product , Randomised Evaluation , Evaluating Minority Patients , Gilead Sciences , American Medical Association , Japan Actemra , Emergency Use Authorization , World Health Organization Model Lists , Essential Medicines , Dow Jones Sustainability Indices , Chugai Pharmaceutical , Roactemra Summary , Therapeutic Goods , Provisional Approval , Roche Products Pty Ltd ,